Sanofi – HealthQuill

Twenty-four European universities have formed a network to impart skills to 10,000 medical students across undergraduate degree programmes to address current and future climate-related health threats, according to a statement from the University of Glasgow.

European body to teach medical students health risks from climate change

Twenty-four European universities have formed a network to impart skills to 10,000 medical students across undergraduate degree programmes to address current and future.

by HealthQuill
October 16, 2024
0 Comments

Regeneron Pharmaceuticals and Sanofi’s drug, Dupixent, got the US regulator’s approval to treat patients with chronic obstructive pulmonary disease.

Drugs Health Pharma

Regeneron-Sanofi’s drug for lung disease gets US approval

Regeneron Pharmaceuticals and Sanofi’s drug, Dupixent, got the US regulator’s approval to treat patients with chronic obstructive pulmonary disease.

by HealthQuill
September 29, 2024
0 Comments

The European Medicines Agency has approved Sanofi S.A.’s Dupixent (dupilumab) therapy as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease, according to a company statement.

Drugs Health Pharma

EMA approves Sanofi’s treatment for obstructive pulmonary disease

The European Medicines Agency has approved Sanofi S.A.’s Dupixent (dupilumab) therapy as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary.

by HealthQuill
July 4, 2024
0 Comments

Semaglutide based weightloss drugs tied to increased suicide risk in a new study

Drugs Health Pharma

EMA expands probe into suicidal thoughts linked to weight loss drugs

HQ Team December 2, 2023: The European Medicines Agency (EMA) is intensifying its investigation into the potential link between certain GLP-1 receptor agonist.

by HealthQuill
December 2, 2023
2 Comments

Drugs Health Pharma

FDA’s advisory panel backs Sanofi, AstraZeneca’s investigational drug for newborns

HQ Team June 9, 2023: An advisory committee of the USFDA has given a “favourable benefit-risk profile” for Sanofi and AstraZeneca’s experimental drug.